Get the Stockscreener App
2.96
6.33%
-0.20
After Hours:
2.98
0.02
+0.68%
Celularity Inc stock is traded at $2.96, with a volume of 138.00K.
It is down -6.33% in the last 24 hours and up +57.45% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$3.16
Open:
$3.14
24h Volume:
138.00K
Relative Volume:
0.61
Market Cap:
$70.89M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.8886
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
-2.31%
1M Performance:
+57.45%
6M Performance:
+18.40%
1Y Performance:
-1.00%
1-Day Range:
$2.95
$3.26
1-Week Range:
$2.95
$4.35
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.96 | 75.68M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
What analysts say about Celularity Inc. stockExponential wealth increase - PrintWeekIndia
What analysts say about Celularity Inc. Equity Warrant stockFree Investment Community - PrintWeekIndia
Is Celularity Inc. stock overhyped or has real potentialFree Investment Community - jammulinksnews.com
What drives Celularity Inc. stock priceMarket-beating performance - PrintWeekIndia
Why Celularity Inc. Equity Warrant stock attracts strong analyst attentionFree AI-Driven Trading Strategies - Newser
Celularity Inc. Stock Analysis and ForecastMassive profits - PrintWeekIndia
Is Celularity Inc. Equity Warrant a good long term investmentPhenomenal capital gains - Autocar Professional
Is Celularity Inc. a good long term investmentExponential wealth increase - Autocar Professional
What drives Celularity Inc. Equity Warrant stock priceBreakthrough profits - Autocar Professional
Celularity Finalizes Private Placement Agreement - TipRanks
Celularity Soared 23.8% Intraday, Could This Biotech Breakout Signal a New Bullish Era? - AInvest
Celularity Inc. Equity Warrant Stock Analysis and ForecastOutstanding capital growth - Autocar Professional
Will Celularity Inc. Equity Warrant stock benefit from AI tech trendsCarefully Curated High Return Stocks - Newser
Celularity Stock Surges Over 8% Amid Florida Stem Cell Policy, New Partnership Boost - AInvest
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):